Design Therapeutics
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6005 Hidden Valley Rd Ste 110, Carlsbad,...Phone Number
(858) 293-4900Website
www.designtx.comRevenue
$11.8 MillionStock Symbol
DSGNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Design Therapeutics
Design Therapeutics is a biopharmaceutical company that specialzies in working on degenerative disorders in patients. They are based in California, United States.Explore more
Design Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Design Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Design Therapeutics
Product Launch: Get notified when Design Therapeutics launches new products
Funding: Get notified immidiatlly once Design Therapeutics has new funding data
Design Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Design Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Design Therapeutics is spiking on competitors!
Click to see if Design Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Design Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at Design Therapeutics
Find 2 more new buyers
Compare Similar Companies to Design Therapeutics
Compare insights from companies similar to Design Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Design Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Design Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Design Therapeutics.
Design Therapeutics financials insights
Gather financial insights about Design Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$45M
2021
Series B
$125M
Design Therapeutics Tech Stack
A closer look at the technologies used by Design Therapeutics
Most Recent Scoops
Project
, according to a mid-level source in medical, is planning to leverage AI-driven predictive modeling (e.g. likely response to treatments, medications, etc.) over the next six to twelve months.
Artificial Intelligence
Project
, according to a mid-level source in medical, is planning to release a request for proposal (RFP) for initiatives related to medical information systems within the next three months.
Request for Proposal (RFP), Clinical Systems, Data Management, Enterprise Software, Software, Healthcare Technology
Project
, according to a mid-level source in medical, is planning to release a request for proposal (RFP) for initiatives related to cyber security within the next six to nine months. Design Therapeutics is expected to decrease workforce due to expected initiative efficiency gains.
Information Security, Request for Proposal (RFP), Cyber Security, Security
Project
, according to a mid-level source in medical, has completed initiatives related to quality improvement within the last twelve months.
Quality Management
Project
Healthcare Operations, Patient Experience
Design Therapeutics News & Media
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
GeneTAC® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m. ET in New York.Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosingDesign Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich’s ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Design Therapeutics
Sign Up For FreeTo access detailed company insights
Design Therapeutics is a biopharmaceutical company that specialzies in working on degenerative disorders in patients. They are based in California, United States.... Read More
